Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase 1 Clinical Trial With Controlled Human Malaria Infection (CHMI) to Evaluate the Safety and Efficacy of the Plasmodium Falciparum Vaccine Candidate FMP012 Administered Intramuscularly With AS01B Adjuvant System in Healthy Malaria-Naïve Adults

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02174978
Recruitment Status : Completed
First Posted : June 26, 2014
Last Update Posted : October 13, 2017
Sponsor:
Collaborators:
Walter Reed Army Institute of Research (WRAIR)
United States Agency for International Development (USAID)
Military Infectious Diseases Research Program (MIDRP)
GlaxoSmithKline
Information provided by (Responsible Party):
U.S. Army Medical Research and Development Command

Brief Summary:
The proposed study is a Phase 1 study with controlled human malaria infection (CHMI) designed primarily to evaluate the safety of the FMP012 combined with AS01B adjuvant system. AS01B is a proprietary current good manufacturing practices (cGMP) grade adjuvant manufactured by GlaxoSmithKline (GSK) Biologicals. It is a formulation based on liposomes mixed with the immunostimulants monophosphoryl lipid (MPL) and Quillaja saponaria (QS)-21. The immunogenicity and efficacy of this new candidate vaccine will be evaluated in addition to safety.

Condition or disease Intervention/treatment Phase
Malaria Biological: FMP012 with AS01B adjuvant system Other: P falciparum Controlled Human Malaria Infection (CHMI) Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 39 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Phase 1 Clinical Trial With Controlled Human Malaria Infection (CHMI) Open-label Dose Safety, Reactogenicity, Immunogenicity, and Efficacy of the Vaccine Candidate Plasmodium Falciparum Malaria Protein (FMP012), Administered Intramuscularly With AS01B Adjuvant System in Healthy Malaria-Naïve Adults
Actual Study Start Date : August 2014
Actual Primary Completion Date : June 2015
Actual Study Completion Date : October 2015

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Malaria

Arm Intervention/treatment
Experimental: Group 1: 10 µg FMP012 adjuvanted AS01B
FMP012 with AS01B adjuvant system: 10 µg FMP012 antigen reconstituted with 500 µL AS01B adjuvant to equal 0.5 mL final volume. Doses administered intramuscular at week 0, 4, 8, and 24. On week week 27, there is a P falciparum Controlled Human Malaria Infection (CHMI) challenge.
Biological: FMP012 with AS01B adjuvant system
Candidate malaria vaccine based on the recombinant protein FMP012, which is Escherichia coli-expressed Plasmodium falciparum cell-traversal protein for ookinetes and sporozoites (PfCelTOS)
Other Name: FMP012 antigen adjuvanted with AS01B

Other: P falciparum Controlled Human Malaria Infection (CHMI)
Experimental: Group 2: 30 µg FMP012 adjuvanted AS01B
FMP012 with AS01B adjuvant system: 30 µg FMP012 antigen reconstituted with 500 µL AS01B adjuvant to equal 0.5 mL final volume administered intramuscular at week 2, 6, 10, and 24. On week week 27, there is a challenge with P falciparum Controlled Human Malaria Infection (CHMI).
Biological: FMP012 with AS01B adjuvant system
Candidate malaria vaccine based on the recombinant protein FMP012, which is Escherichia coli-expressed Plasmodium falciparum cell-traversal protein for ookinetes and sporozoites (PfCelTOS)
Other Name: FMP012 antigen adjuvanted with AS01B

Other: P falciparum Controlled Human Malaria Infection (CHMI)
Infectivity control
Non-immunized infectivity control challenged with P falciparum Controlled Human Malaria Infection (CHMI)
Other: P falciparum Controlled Human Malaria Infection (CHMI)



Primary Outcome Measures :
  1. Number of solicited adverse events (AE) [ Time Frame: 7 days after each vaccination ]
  2. Number of unsolicited AEs [ Time Frame: 28 days after each vaccination ]
  3. Occurrence of serious adverse events (SAE) at any time during the study period (enrollment to final follow-up visit) [ Time Frame: 12 months after vaccination ]

Secondary Outcome Measures :
  1. Anti-FMP012 antibody titers in serum [ Time Frame: 12 months ]
  2. Time to parasitemia by blood smear after the P falciparum challenge [ Time Frame: 12 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy adults (male or non-pregnant, non-lactating female) 18 to 50 years of age (inclusive) at the time of screening
  • If the subject is female,

    • Non-childbearing potential (ie, either surgically sterilized or one year post-menopausal), abstinent or using adequate contraceptive precautions (eg, intrauterine contraceptive device; oral contraceptives; diaphragm or condom in combination with contraceptive jelly, cream or foam; Norplant® or Depo-Provera®) during this study and must agree to continue such precautions until three months after challenge
    • A negative pregnancy test at the time of enrollment
  • Free of significant health problems as established by medical history, laboratory, and clinical examination before entering the study
  • Subjects must have low cardiac risk factors according to the National Health and Nutrition Examination Survey (NHANES) I criteria, medical history and family history, blood pressure measurements, and a normal or normal variant ECG
  • Available to participate and reachable by phone for duration of study (approximately 8-14 months) and reachable by phone at the 6 month post Controlled Human Malaria Infection (CMHI) follow-up
  • No plans to travel to outside the Washington DC area between the day of challenge and either completion of treatment course (post-challenge) or, if subject remains uninfected, 28 days post-challenge
  • No plans to travel to a malaria endemic area during the course of the study
  • Written informed consent must be obtained from the subject before screening procedures are performed
  • Subjects must score at least 80% correct on a multiple-choice quiz that assesses their understanding of this study
  • If a subject is active duty military, he or she must obtain approval from his or her supervisor per Walter Reed Army Institute of Rese (WRAIR) Policy 11-45

Exclusion Criteria:

  • Any history of malaria infection
  • History of travel to P falciparum endemic areas in the 3 months prior to day of first vaccination (Vaccination Groups) or day of challenge (Infectivity Control Group)
  • Any history of receiving a malaria vaccine
  • Receipt of any licensed vaccine within 7 days prior to first vaccination (Note: subjects are encouraged to get recommended licensed preventive vaccinations during the course of the study but are requested to schedule any routine preventive vaccinations for at least 7 days before or after a scheduled FMP012/AS01B vaccination day)
  • History of receipt of malaria prophylaxis during the 2 months prior to day of first vaccination (Vaccination Groups) or day of challenge (Infectivity Control Group)
  • History of use of any antibiotics with significant antimalarial activity (examples include tetracycline, doxycycline, clindamycin, azithromycin, and sulfa drugs) during the course of the study period (period starting one month prior to challenge, Infectivity Control Group)
  • Use of any investigational or non-registered drug or vaccine within 30 days preceding the first dose of study vaccine or planned use during the study period.
  • Any history of allergic reaction or anaphylaxis to previous vaccination (Vaccination Groups)
  • Allergy to egg protein (Vaccination Groups)
  • Pregnant (positive β-human chorionic gonadotropin test, β-HCG) or lactating female at screening or plans to become pregnant or breastfeed from the time of enrollment until three months after challenge
  • Allergy to antimalarial drugs or use of medications known to interact with chloroquine (CQ)
  • Significant (eg, systemic) hypersensitivity reactions to mosquito bites (local hypersensitivity reactions at the site of mosquito bites are not an exclusion criterion)
  • History of sickle cell disease
  • History of psoriasis or porphyria
  • History of splenectomy
  • Any confirmed or suspected immunodeficiency, including HIV infection
  • Administration of chronic (defined as more than 14 days) immunosuppressive drugs or other immune-modifying drugs within 6 months of vaccination
  • History of autoimmune disease
  • Family history of congenital or hereditary immunodeficiency
  • Acute or chronic, clinically significant, pulmonary, cardiovascular, endocrine, hepatic, or renal functional abnormality, as determined by history, physical examination, or laboratory evaluation
  • Chronic or active neurologic disease including seizure disorder and chronic migraine headaches
  • Administration of immunoglobulins and/or any blood products within the three months preceding the first dose of study vaccine or any planned administration during the study period
  • Any abnormal baseline laboratory screening tests to include:

    • Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) above normal range,
    • Creatinine above normal range,
    • Hemoglobin out of normal range,
    • Platelet count out of normal range, or
    • Total white blood cell (WBC) count out of normal range
  • Seropositive for HIV or Hepatitis C virus (HCV) or hepatitis B surface antigen (HBsAg) positive
  • Hepatomegaly, right upper quadrant abdominal pain or tenderness
  • An abnormal baseline screening ECG suggestive of cardiac disease as determined by a clinical investigator
  • Suspected or known current alcohol or drug abuse as determined from the medical history or by physical examination
  • Any other significant finding that in the opinion of the PI would increase the risk of having an adverse outcome from participating in this study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02174978


Locations
Layout table for location information
United States, Maryland
Clinical Trials Center, WRAIR
Silver Spring, Maryland, United States, 20910
Sponsors and Collaborators
U.S. Army Medical Research and Development Command
Walter Reed Army Institute of Research (WRAIR)
United States Agency for International Development (USAID)
Military Infectious Diseases Research Program (MIDRP)
GlaxoSmithKline
Investigators
Layout table for investigator information
Principal Investigator: Jason W Bennett, LTC, MC Malaria Vaccine Branch, Military Malaria Research Program, WRAIR

Layout table for additonal information
Responsible Party: U.S. Army Medical Research and Development Command
ClinicalTrials.gov Identifier: NCT02174978     History of Changes
Other Study ID Numbers: S-14-02
First Posted: June 26, 2014    Key Record Dates
Last Update Posted: October 13, 2017
Last Verified: October 2017

Keywords provided by U.S. Army Medical Research and Development Command:
Malaria vaccine

Additional relevant MeSH terms:
Layout table for MeSH terms
Malaria
Protozoan Infections
Parasitic Diseases
Vaccines
Immunologic Factors
Physiological Effects of Drugs